Qurient Co Ltd (115180):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8265)
◆英語タイトル:Qurient Co Ltd (115180) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8265
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:25
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Qurient Co Ltd (Qurient) is a pharmaceutical company that offers development of new drugs for unmet medical needs. The company provides portfolio of pipeline products such as Q301, Q203, Q701, 5LO INH and CDK7 INH, among others. It is developing products for the treatment of atopic dermatitis; extensively drug-resistant tuberculosis (XDR) and multi drug resistant (MDR) and totally drug resistant (TDR) tuberculosis (TB); asthama and cancer, among others. Qurient works in partnership with research institutes, CRO and research hospitals for development of new therapeutics. The company offers services in partnership of CMO for research and development of new therapeutics. Qurient is headquartered in Seongnam, South Korea.

Qurient Co Ltd (115180) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Qurient Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Qurient Raises USD15.5 Million in Series F Venture Financing 10
Qurient Raises USD3 Million in Series E Venture Financing 12
Qurient Raises US$4 Million In Venture Financing 13
Partnerships 14
Qurient Enters into Agreement with Lead Discovery Center 14
Licensing Agreements 15
Lead Discovery Center Enters into Licensing Agreement with Qurient 15
Qurient Enters Into Licensing Agreement with Max Planck Society and Lead Discovery Center 16
Infectex Enters Into Licensing Agreement With Qurient For Tuberculosis Drug Q203 17
Max Planck Institute of Biochemistry And Lead Discovery Center Enter Into Licensing Agreement With Qurient For Kinase Inhibitor 18
Equity Offering 20
Qurient Raises USD25.7 Million in IPO 20
Qurient Co Ltd – Key Competitors 21
Qurient Co Ltd – Key Employees 22
Qurient Co Ltd – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Clinical Trials 24
Jun 22, 2017: Infectex Successfully Completes Phase 1 Clinical Study of Q203 for Treatment of Tuberculosis 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Qurient Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Qurient Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Qurient Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Qurient Raises USD15.5 Million in Series F Venture Financing 10
Qurient Raises USD3 Million in Series E Venture Financing 12
Qurient Raises US$4 Million In Venture Financing 13
Qurient Enters into Agreement with Lead Discovery Center 14
Lead Discovery Center Enters into Licensing Agreement with Qurient 15
Qurient Enters Into Licensing Agreement with Max Planck Society and Lead Discovery Center 16
Infectex Enters Into Licensing Agreement With Qurient For Tuberculosis Drug Q203 17
Max Planck Institute of Biochemistry And Lead Discovery Center Enter Into Licensing Agreement With Qurient For Kinase Inhibitor 18
Qurient Raises USD25.7 Million in IPO 20
Qurient Co Ltd, Key Competitors 21
Qurient Co Ltd, Key Employees 22

List of Figures
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Qurient Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Qurient Co Ltd (115180):製薬・医療:M&Aディール及び事業提携情報(Qurient Co Ltd (115180) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆